Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Impact of Metabolic Parameters of 18F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma

NORIFUMI HARIMOTO, KOUKI HOSHINO, RYO MURANUSHI, KEI HAGIWARA, TAKAHIRO YAMANAKA, NORIHIRO ISHII, MARIKO TSUKAGOSHI, TAKAMICHI IGARASHI, HIROSHI TANAKA, AKIRA WATANABE, NORIO KUBO, KENICHIROU ARAKI, HIROYASU TOMONAGA, TETSUYA HIGUCHI, YOSHITO TSUSHIMA and KEN SHIRABE
Anticancer Research February 2019, 39 (2) 971-977; DOI: https://doi.org/10.21873/anticanres.13201
NORIFUMI HARIMOTO
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nharimotoh1@gunma-u.ac.jp
KOUKI HOSHINO
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYO MURANUSHI
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEI HAGIWARA
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAHIRO YAMANAKA
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIHIRO ISHII
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIKO TSUKAGOSHI
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
2Department of Innovative Cancer Immunotherapy, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAMICHI IGARASHI
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI TANAKA
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIRA WATANABE
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO KUBO
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENICHIROU ARAKI
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYASU TOMONAGA
3Department of Diagnostic Radiology and Nuclear Medicine, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUYA HIGUCHI
3Department of Diagnostic Radiology and Nuclear Medicine, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHITO TSUSHIMA
3Department of Diagnostic Radiology and Nuclear Medicine, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEN SHIRABE
1Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The aim of this study was to identify the prognostic impact of metabolic parameters of 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) in patients with intrahepatic cholangiocarcinoma (IHCC) undergoing hepatic resection. Patients and Methods: Twenty-four patients with IHCC who underwent surgical resection were enrolled and 18F-FDG PET parameters maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured, as well as overall and recurrence-free survival. Results: High TLG was significantly associated with large tumor size and high carbohydrate antigen 19-9 level. Patients with high SUVmax, high MTV or high TLG had a significantly worse prognosis regarding both overall and recurrence-free survival than those with low SUVmax, low MTV and low TLG, respectively. Multivariate Cox proportional hazards analysis identified that high TLG significantly influenced both overall and recurrence-free survival. Conclusion: Preoperative assessment of TLG by 18F-FDG PET might be a useful prognostic predictor after hepatic resection in patients with IHCC.

  • Intrahepatic cholangiocarcinoma
  • metabolic tumor volume
  • total lesion glycolysis
  • lymph node metastasis
  • prognosis

Intrahepatic cholangiocarcinoma (IHCC) is primary liver cancer arising in the intrahepatic bile ducts, which accounts for 5-10% of primary liver cancers and is the second most frequent form of primary hepatic malignancies in adults after hepatocellular carcinoma (1, 2). Radical surgical resection is the only effective curative treatment, but the survival rates for patients with IHCC remain unfavorable, although advances in diagnostic and surgical approaches to IHCC have been achieved. There are many preoperative prognostic factors in IHCC (3-6). Lymph node metastasis is reportedly the most significant predictor of poor outcome in IHCC, but extended lymphadenectomy does not improve survival (3, 5, 6). Additionally, preoperative diagnosis of lymph node metastasis is still difficult despite the use of computed tomographic (CT) or positron-emission tomographic (PET) scan. Lymphatic invasion or vascular invasion were reported to be prognostic factors, but these are postoperative factors. R0 resection was also reported to be an independent predictor of long-term survival. Surgical resection is still the most effective treatment in the modern era.

18F-Fluorodeoxyglucose (FDG) PET has been used in the diagnostic imaging of many cancer types such as lung, pancreatic, and metastatic liver cancer. Recent meta-analyses showed that various FDG PET parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were prognostic factors in multiple types of malignancies (7-9). But information on the prognostic value of FDG-PET in IHCC is limited. Therefore, the aim of this study was to identify preoperative predictors of prognosis in patients with IHCC undergoing hepatic resection, and examine the impact of metabolic parameter of 18F-FDG-PET/CT in those patients.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Overall (A) and recurrence-free (B) survival curves after hepatic resection in patients with intrahepatic cholangiocarcinoma according to TLG (total lesion glycolysis). These curves show that patients with TLG>352.8 cm3 had a significantly poorer prognosis.

Patients and Methods

Patient characteristics. This study enrolled 24 patients with IHCC who had undergone surgical resection at the Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan, between April 2007 and December 2017. All patients had a confirmed pathological diagnosis of a malignancy arising from the intrahepatic cholangiocarcinoma. Patient demographic and clinical characteristics, including perioperative factors, tumor characteristics and survival were analyzed, and factors predicting overall (OS) and recurrence-free (RFS) survival were evaluated by univariate and multivariate analyses. The study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration and was approved by our Institutional Review Board (approval number: 2017-237).

18F-FDG/PET imaging. PET imaging was performed within 1 month before hepatic resection using a PET/CT scanner (Discovery STE; GE Healthcare, CA, USA) with a 700 mm field of view at Gunma University Hospital and another PET/CT scanner (Aquideo, PCA-7000B; Toshiba, Tokyo, Japan) at Hidaka Hospital. The patients fasted for at least 6 h before PET imaging. FDG PET/CT image acquisition, reconstruction, and attenuation correction were performed as previously described (10). All 18F-FDG images were interpreted by two experienced nuclear physicians (H.T. and T.Y.). The interpreting physicians were unaware of the patient's clinical history and data. Tracer uptake in the primary tumor was defined as positive if the uptake was higher than that of the normal mediastinum. Discrepant results were resolved by consensus review. For the semiquantitative analysis, functional images for the SUV were produced using attenuation-corrected transaxial images, the injected dose of 18F-FDG, the patient's body weight, and the cross-calibration factor between PET and the dose calibrator. SUV was defined as follows: SUV=radioactive concentration in the region of interest (ROI) [MBq/g]/injected dose (MBq)/patient's body weight (g). The ROI was manually drawn over the primary tumor on the SUV images. When the tumor was larger than 1 cm in diameter or the shape of the tumor was irregular or multifocal, a ROI of approximately 1 cm in diameter was drawn over the area corresponding to the maximal tracer uptake. ROI analysis was conducted by a nuclear physician with the aid of corresponding CT scans. The SUVmax in the ROI was used as a representative value for the assessment of FDG uptake in the lesion. CT scan for the purpose of initial staging was carried out with intravenous contrast medium. CT images were interpreted by the two Board-certified radiologists (T.H. and Y.T.). Syngo.via software (Siemens Medical Solutions, Erlangen, Germany) at the Gunma University Hospital on a workstation to automatically calculate the MTV and TLG. MTVs were defined as the tumor volume inside the tumor boundaries using SUV thresholds that were 60% of the tumor SUVmax. TLGs were calculated by multiplying the mean SUV by the tumor volume inside the tumor boundaries.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Comparison of the clinicopathological factors in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma according to total lesion glycolysis. Continuous data are expressed as mean±standard deviation.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Overall (A) and recurrence-free (B) survival curves after hepatic resection in patients with intrahepatic cholangiocarcinoma according to MTV (metabolic tumor volume). These curves show that patients with MTV>81.2 cm3 had a significantly poorer prognosis.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Overall (A) and recurrence-free (B) survival curves after hepatic resection in patients with intrahepatic cholangiocarcinoma according to maximum standardized uptake value. These curves show that patients with SUVmax>9.6 had a significantly poorer prognosis.

Preoperative calculation of the cut-off value of the SUVmax, MTV and TLG. The receiver operating characteristics (ROC) curves of preoperative 18F-FDG/PET parameters were analyzed, and OS was predicted by comparing the area under the ROC curve (AUC). The best cut-off value was 9.6 for SUVmax (sensitivity=71.43%; specificity=99.42%; AUC=0.798), 81.2 for MTV (sensitivity=85.71%; specificity=82.35%; AUC=0.882) and 352.8 for TLG (sensitivity= 85.71%; specificity=81.27%; AUC=0.9076).

Surgical procedures. All patients underwent dynamic CT imaging preoperatively. The details of our surgical techniques and patient follow-up methods were reported previously (5). Major hepatectomy with bile duct resection was performed when bile duct invasion was suspected to have affected the first hepatic duct. Partial hepatectomy was performed for peripheral IHCC without bile duct invasion. When we considered it desirable to confirm the surgical margins, the resected specimen was sent for frozen pathology. The right and left lobes of the liver have different routes of lymphatic drainage; therefore, the technique for lymph node dissection was tailored to the location of the primary tumor. Postoperative surgical complications were recorded according to the Clavien-Dindo classification (11).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Cox proportional hazard model of the association of all clinical characteristics with overall survival using univariate and multivariate analyses.

Follow-up strategy and recurrence pattern. After discharge, all patients were examined for recurrence by ultrasonography and tumor markers by CT every 3 months. When recurrence was suspected, additional examinations such as MRI or 18F-FDG/PET were performed.

Histopathological examination. All of the resected specimens were cut into serial 5- to 10-μm-thick slices and fixed in 10% formalin. The sections were stained with hematoxylin and eosin. Tumor differentiation, microvascular invasion, intrahepatic metastasis were assessed by the pathologist according to the criteria of the Liver Cancer Study Group of Japan (12). Histologically, all cases were identified as mass-forming type IHCC.

Statistical analysis. The associations of continuous and categorical variables with the relevant outcome variables were assessed using Student's t-test and the chi-square test, respectively. Patient survival was analyzed using the Kaplan–Meier method and groups compared using the log-rank test. Uni- and multivariate analyses were performed using a logistic regression model. To identify prognostic factors, some variables which were found to have independent association in univariate analysis (except MTV) were included in a multivariate Cox proportional model to analyze both OS and RFS because MTV was a confounding factor Lymph node metastasis is reportedly the most significant predictor of poor outcome in IHCC (5, 6), and therefore lymph node metastasis was included in the multivariate analysis. Statistical analyses were performed using JMP software (version 12.2.0; SAS Institute, Cary, NC, USA). Results with a p-value of less than 0.05 were considered statistically significant.

Results

The clinicopathological characteristics of the patients according to TLG (>352.8 cm3 and ≤352.8 cm3) are shown in Table I. A high TLG was significantly associated with large tumor size and high carbohydrate antigen 19-9 (CA19-9) level. The OS and RFS curves of the patients according to TLG are illustrated in Figure 1. Patients with high TLG had a significantly worse prognosis regarding both OS and RFS than did patients with low TLG. The OS and RFS curves according to MTV and SUVmax are illustrated in Figures 2 and 3, respectively. Patients with high (>81.2 cm3) MTV had a significantly worse prognosis regarding both OS and RFS than did patients with low MTV. Moreover, patients with high (>9.6) SUVmax had a significantly worse OS and RFS than did patients with low SUVmax.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Cox proportional hazard model of the association of all clinical characteristics with recurrence-free survival using univariate and multivariate analyses.

The prognostic factors for OS and RFS, according to univariate analyses, are shown in Tables II and III. The significant prognostic factors for OS in univariate analysis were low serum albumin level, high SUVmax, high MTV, high TLG and CA19-9 >100 U/ml. The significant prognostic factors for RFS were high SUVmax, high TLG, high MTV, tumor size >5 cm, lymph node metastasis, CA19-9 >100 U/ml and the presence of microvascular invasion. Multivariate analysis identified two factors of poor prognosis that influenced OS (high SUVmax and high TLG), and three that influenced RFS (high TLG, tumor size >5 cm and microvascular invasion).

Discussion

According to multivariate analysis, in this retrospective study, high TLG was an independent predictor of both OS and RFS after curative hepatic resection in patients with ICC. In this multivariate analysis, high SUVmax was an independent predictor of OS, but not RFS. Consequently, TLG reflects the malignant potential of IHCC much better than SUVmax.

SUVmax in IHCC was reported as independent prognostic factor. Ma et al. reported SUVmax of more than 8 reflecd poorer prognosis in patients with TNM stage I and II cholangiocarcinoma (13). Seo et al. also reported SUVmax>8.5 as an independent predictor of postoperative recurrence in multivariate analysis (14). SUVmax is a measurement of a single pixel with the highest radiotracer concentration in the region of interest, which means it does not reflect the nature of the whole tumor. MTV represents the active metabolic tumor volume and then TLG was calculated by multiplying the tumor volume by the mean SUV of tumor. Our data show that the group with a high MTV had a larger mean tumor size and higher CA19-9 level. MTV and TLG are reported to have a prognostic significance in many cancer types. Yoo et al. reported that TLG was a better prognostic predictor than SUVmax in patients with gallbladder carcinoma (15). Aditionally, Lee et al. reported TLG to be a better prognostic predictor than SUVmax in patients with distal bile duct adenocarcinoma after curative resection (16). There are few reports on MTV and TLG in IHCC. Recently, Ikeno et al. reported a high MTV to be associated with KRAS mutation and poor postoperative outcomes in 50 patients with resected IHCC, suggesting that the MTV of IHCC as measured by 18F-FDG-PET may provide useful information for tumor molecular profiles and prognosis (17). Some reports investigated metabolic parameters in patients with IHCC, but one also included biliary tract cancer (18) and the other included non-surgical cases (19).

To date, surgical resection remains the only potentially curative treatment for IHCC, but early recurrence is common even in patients who have undergone curative resection. A better understanding of the preoperative factors associated with poor prognosis in patients with IHCC scheduled for curative resection would inform decisions about the need for additional preoperative treatment of high-risk patients, such as neoadjuvant chemotherapy. The evidence supporting the therapeutic benefits of neo- and adjuvant treatment relies on retrospective series or relatively small prospective studies (20). It is essential to be able to identify patients at risk of recurrence despite complete curative resection of IHCC so that neo- and adjuvant chemotherapy can be more effectively targeted and outcomes can be improved.

Our study had some limitations. The sample was relatively small, which made it difficult to evaluate the outcomes of curative resection; however, few previous studies have examined the role of pre- and postoperative treatment of IHCC after curative resection.

In conclusion, we found that preoperative assessment of TLG by 18F-FDG PET might be a useful prognostic predictor after hepatic resection in patients with IHCC. Those patients with association of high TLG may need additional preoperative chemotherapy.

Footnotes

  • Conflicts of Interest

    The Authors declare no conflicts of interest.

  • Received December 14, 2018.
  • Revision received December 20, 2018.
  • Accepted December 21, 2018.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Rizvi S,
    2. Gores GJ
    : Pathogenesis, diagnosis and management of cholangiocarcinoma. Gastroenterology 145: 1215-1229, 2013.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Patel T
    : Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357, 2001.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Choi SB,
    2. Kim KS,
    3. Choi JY,
    4. Park SW,
    5. Choi JS,
    6. Lee WJ,
    7. Chung JB
    : The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 16(11): 3048-3056, 2009.
    OpenUrlCrossRefPubMed
    1. Endo I,
    2. Gonen M,
    3. Yopp AC,
    4. Dalal KM,
    5. Zhou Q,
    6. Klimstra D,
    7. D'Angelica M,
    8. DeMatteo RP,
    9. Fong Y,
    10. Schwartz L,
    11. Kemeny N,
    12. O'Reilly E,
    13. Abou-Alfa GK,
    14. Shimada H,
    15. Blumgart LH,
    16. Jarnagin WR
    : Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248(1): 84-96, 2008.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Shimada M,
    2. Yamashita Y,
    3. Aishima S,
    4. Shirabe K,
    5. Takenaka K,
    6. Sugimachi K
    : Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg 88: 1463-1466, 2001.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Uchiyama K,
    2. Yamamoto M,
    3. Yamaue H,
    4. Ariizumi S,
    5. Aoki T,
    6. Kokudo N,
    7. Ebata T,
    8. Nagino M,
    9. Ohtsuka M,
    10. Miyazaki M,
    11. Tanaka E,
    12. Kondo S,
    13. Uenishi T,
    14. Kubo S,
    15. Yoshida H,
    16. Unno M,
    17. Imura S,
    18. Shimada M,
    19. Ueno M,
    20. Takada T
    : Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 18: 443-452, 2011.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Muralidharan V,
    2. Kwok M,
    3. Lee ST,
    4. Lau L,
    5. Scott AM,
    6. Christophi C
    : Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases. J Nucl Med 53(9): 1345-1351, 2012.
    OpenUrlAbstract/FREE Full Text
    1. Huang Y,
    2. Feng M,
    3. He Q,
    4. Yin J,
    5. Xu P,
    6. Jiang Q,
    7. Lang J
    : Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients. Medicine (Baltimore) 96(17): e6721, 2017.
    OpenUrl
  7. ↵
    1. Im HJ,
    2. Zhang Y,
    3. Wu H,
    4. Wu J,
    5. Daw NC,
    6. Navid F,
    7. Shulkin BL,
    8. Cho SY
    : Prognostic value of metabolic and volumetric parameters of FDG PET in pediatric osteosarcoma: A hypothesis-generating study. Radiology 287(1): 303-312, 2018.
    OpenUrl
  8. ↵
    1. Kaira K,
    2. Higuchi T,
    3. Naruse I,
    4. Arisaka Y,
    5. Tokue A,
    6. Altan B,
    7. Suda S,
    8. Mogi A,
    9. Shimizu K,
    10. Sunaga N,
    11. Hisada T,
    12. Kitano S,
    13. Obinata H,
    14. Yokobori T,
    15. Mori K,
    16. Nishiyama M,
    17. Tsushima Y,
    18. Asao T
    : Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging 45(1): 56-66, 2018.
    OpenUrl
  9. ↵
    1. Dindo D,
    2. Demartines N,
    3. Clavien PA
    : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213, 2004.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Liver Cancer Study Group of Japan
    : General rules for the clinical and pathological study of primary liver cancer, Second English edition, pp. 34-35, Kanehara& Co., Tokyo, 2003.
  11. ↵
    1. Ma KW,
    2. Cheung TT,
    3. She WH,
    4. Chok KSH,
    5. Chan ACY,
    6. Dai WC,
    7. Chiu WH,
    8. Lo CM
    : Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer. World J Surg 42(3): 823-834, 2018.
    OpenUrl
  12. ↵
    1. Seo S,
    2. Hatano E,
    3. Higashi T,
    4. Nakajima A,
    5. Nakamoto Y,
    6. Tada M,
    7. Tamaki N,
    8. Iwaisako K,
    9. Mori A,
    10. Doi R,
    11. Ikai I,
    12. Uemoto S
    : Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 143(6): 769-777, 2008.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Yoo J,
    2. Young J,
    3. Choi JY,
    4. Lee KT,
    5. Heo JS,
    6. Park SB,
    7. Moon SH,
    8. Choe YS,
    9. Lee KH,
    10. Kim BY
    : Prognostic significance of volume-based metabolic parameters by 18F-FDG PET/CT in gallbladder carcinoma. Nucl Med Mol Imaging 46: 201-206, 2012.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Lee EJ,
    2. Chang SH,
    3. Lee TY,
    4. Yoon SY,
    5. Cheon YK,
    6. Shim CS,
    7. So Y,
    8. Chung HW
    : Prognostic value of FDG-PET/CT total lesion glycolysis for patients with resectable distal bile duct adenocarcinoma. Anticancer Res 35: 6985-6991, 2015.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Ikeno Y,
    2. Seo S,
    3. Iwaisako K,
    4. Yoh T,
    5. Nakamoto Y,
    6. Fuji H,
    7. Taura K,
    8. Okajima H,
    9. Kaido T,
    10. Sakaguchi S,
    11. Uemoto S
    : Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis. J Transl Med 16(1): 95, 2018.
    OpenUrl
  16. ↵
    1. Cho KM,
    2. Oh DY,
    3. Kim TY,
    4. Lee KH,
    5. Han SW,
    6. Im SA,
    7. Kim TY,
    8. Bang YJ
    : Metabolic characteristics of advanced biliary tract cancer using 18F-fluorodeoxyglucose positron emission tomography and their clinical implications. Oncologist 20(8): 926-933, 2015.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Lee Y,
    2. Yoo IR,
    3. Boo SH,
    4. Kim H,
    5. Park HL,
    6. Hyun OJ
    : The role of F-18 FDG PET/CT in intrahepatic cholangiocarcinoma. Nucl Med Mol Imaging 51(1): 69-78, 2017.
    OpenUrl
  18. ↵
    1. McNamara MG,
    2. Walter T,
    3. Horgan AM,
    4. Amir E,
    5. Cleary S,
    6. McKeever EL,
    7. Min T,
    8. Wallace E,
    9. Hedley D,
    10. Krzyzanowska M,
    11. Moore M,
    12. Gallinger S,
    13. Greig P,
    14. Serra S,
    15. Dawson LA,
    16. Knox JJ
    : Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol 38: 382-387, 2015.
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 39 (2)
Anticancer Research
Vol. 39, Issue 2
February 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Metabolic Parameters of 18F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Impact of Metabolic Parameters of 18F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma
NORIFUMI HARIMOTO, KOUKI HOSHINO, RYO MURANUSHI, KEI HAGIWARA, TAKAHIRO YAMANAKA, NORIHIRO ISHII, MARIKO TSUKAGOSHI, TAKAMICHI IGARASHI, HIROSHI TANAKA, AKIRA WATANABE, NORIO KUBO, KENICHIROU ARAKI, HIROYASU TOMONAGA, TETSUYA HIGUCHI, YOSHITO TSUSHIMA, KEN SHIRABE
Anticancer Research Feb 2019, 39 (2) 971-977; DOI: 10.21873/anticanres.13201

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Impact of Metabolic Parameters of 18F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma
NORIFUMI HARIMOTO, KOUKI HOSHINO, RYO MURANUSHI, KEI HAGIWARA, TAKAHIRO YAMANAKA, NORIHIRO ISHII, MARIKO TSUKAGOSHI, TAKAMICHI IGARASHI, HIROSHI TANAKA, AKIRA WATANABE, NORIO KUBO, KENICHIROU ARAKI, HIROYASU TOMONAGA, TETSUYA HIGUCHI, YOSHITO TSUSHIMA, KEN SHIRABE
Anticancer Research Feb 2019, 39 (2) 971-977; DOI: 10.21873/anticanres.13201
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study
  • Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
  • Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • Intrahepatic cholangiocarcinoma
  • metabolic tumor volume
  • total lesion glycolysis
  • lymph node metastasis
  • prognosis
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire